Conclusion Authentic needle and drug-containing devices were used in order to provide a realistic assessment of the potential for limitations of usability with the SCTE-AI device. Results of this usability validation study indicate the low potential for physical harm associated with use of the...
Introduction & Objectives: Xyosted is the first Food and Drug Administration (FDA)-approved testosterone enanthate product aimed to provide a weekly, self-administered injector for subcutaneous delivery of testosterone. This is the first non-industry sponsored post-market study to evaluate...
Introduction: Xyosted® is a subcutaneous testosterone enanthate-autoinjector (SCTE-AI) which was approved by the Food and Drug Administration in 2018 for patient-administered weekly testosterone replacement therapy (TRT). Objective: This is the largest non-industry sponsored post-market study...
Comparison of Outcomes for Hypogonadal Men Treated with Intramuscular Testosterone Cypionate Versus Subcutaneous Testosterone Enanthate (2020) Introduction Intramuscular testosterone cypionate (IM-TC) is the conventional treatment option for hypogonadal men with baseline serum total...
Abstract Context: Injections with intramuscular testosterone esters have been available for almost 8 decades and not only result in predictable serum testosterone levels but are also the most inexpensive modality. However, they are difficult to self-administer and associated with some...